Word count: 3815 words Abstract RNA splicing is a key mechanism linking genetic variation with psychiatric disorders.
Introduction
Genomic studies have identified numerous common single nucleotide polymorphisms (SNPs) that are robustly associated with psychiatric disorders; the challenge is now to understand the underlying pathophysiological mechanisms 1 . Most of these SNPs are non-coding [2] [3] [4] , implying that they mediate disease associations by influencing aspects of RNA expression. Of the various mechanisms of RNA regulation, the possibility that psychiatric risk SNPs might influence RNA splicing is particularly appealing, given its exquisite, cell type-specific regulation and its key role in determining neuronal properties 5 . Consistent with this hypothesis, at a global level, cellular studies emphasise RNA splicing as a key mechanism mediating the effect of disease-associated, non-coding variants in complex disorders, including schizophrenia 6 . Similarly, in human brain, genomic regions associated with schizophrenia are enriched for genes that show differential isoform usage across neurodevelopment 7 , implicating many schizophrenia-associated risk loci in the regulation of the expression of specific RNA transcripts. Consistent with these findings, examples of associations between psychiatric risk-associated loci and the abundance of novel, alternatively spliced transcripts are beginning to emerge [8] [9] [10] , complementing numerous reports of altered splicing patterns in the brains of psychiatric cases, compared to controls [11] [12] [13] .
Splicing varies extensively across human development and aging 7 , and between tissues. The brain exhibits one of the highest levels of splicing diversity and prominent use of tissue specific exons, microexons and splicing factors [14] [15] [16] [17] [18] .
However, despite extensive efforts to improve the annotation of the human genome 19 , the alternative splicing patterns of many genes remain poorly described, especially in brain, and novel coding exons (many of which are enriched within brainexpressed genes 20, 21 ) and transcripts are continually being discovered. This is due to the limited availability of high-quality, post-mortem human tissue and to technical limitations associated with standard approaches: most rely on short-read RNA-Seq and the reconstruction of fragmented sequences making the disambiguation of fulllength transcripts difficult, particularly for large and complex genes. Benchmarking studies have shown that short-read RNA-Seq methodologies are unable to accurately reconstruct and quantitate the majority of transcript and protein isoforms 22, 23 .
The relative lack of knowledge about the splicing of individual human genes is typified by CACNA1C. CACNA1C encodes the Ca V 1.2 voltage-gated calcium channel (VGCC) alpha 1 subunit and is a leading genomically-informed candidate gene for multiple psychiatric disorders 2, 3, 24, 25 . However, it is not known how its expression and/or splicing is altered in illness, or in association with genetic risk for it 26 . The CACNA1C gene is large (cDNA <13433 nucleotides [nt] , 2209 amino acids [aa] ) and complex, with at least 50 annotated exons and 31 predicted transcripts (Gencode 27; Figure 1A ) 17 . Its size and complexity makes accurate transcript identification and quantification by standard gene expression measures extremely difficult;
consequently, the true full-length protein sequence of isoforms remains unclear.
Information on the transcript diversity of human neuronal VGCC subunits is sparse:
most studies have focused on rodents 18 , or human cardiac tissue 27, 28 ; the sole study examining VGCC splicing in human brain used a single adult sample 29 . This information is significant, both in terms of understanding pathophysiological mechanisms and for the development of novel pharmacological agents, because CACNA1C encodes multiple alternatively spliced transcripts, which result in functionally and pharmacologically distinct channels 30, 31 .
To address these unknowns, we developed a straightforward and cost-effective approach using a long-read sequencing technology [32] [33] [34] . We combined long-range RT-PCR with long-read nanopore sequencing and a novel bioinformatics pipeline to characterise full-length CACNA1C coding sequences (CDSs) in post-mortem human brain. We show that the transcript structure of human CACNA1C is substantially more complex than currently appreciated, with numerous novel transcripts and isoforms containing unannotated exons, novel splicing junctions, and in-frame deletions that are predicted to alter the protein sequence and function.
Methods

Sample preparation and sequencing
Post-mortem brain tissue from three adult donors in the Lieber Institute for Brain ]) were amplified using PCR, and barcoded and sequenced (across two runs; six samples common to both runs) using
Oxford Nanopore Technology's MinION.
Data analysis and code availability
Our novel data analysis pipeline is available from: https://github.com/twrzes/TAQLoRe. 2D
pass reads (i.e.: those with a q-score of >=9) with an identified barcode were mapped to the transcriptome (hg38, ENSEMBL v82) using a HPC version of BLAT (pblat-cluster v0.3, available from http://icebert.github.io/pblat-cluster/
37
) and to the CACNA1C meta-gene containing known exonic sequences using GMAP version 2017-04-24 38 . Reads mapping uniquely to CACNA1C, and with at least 50% of their length mapped were retained for further analysis.
To identify potential novel exons, we mined the alignments of the reads to the transcriptome for inserts of at least 9 nucleotides in length located at the junctions between annotated exons. To further characterize candidate novel exons, we mapped the corresponding reads to the genome using LAST v926 39 . We retained candidate exons located within the expected intronic sequences, and at least 6 nt away from existing exons. Novel exonic sequences were subsequently introduced to the CACNA1C metagene (concatenation of all exons) and reads were mapped again to this new model using GMAP to enable further characterization of alternative splicing and quantification of transcript expression.
To characterize novel exon junctions, we mapped all the reads to the human genome (hg38) using LAST v926
39
. We identified all exon junctions that showed perfect and contiguous mapping (no sequencing errors nor insertion/deletions) of the read to the genome and used canonical acceptor and donor splice sites. We then used this comprehensive set of exon junctions to correct reads with sequencing errors at mapping breakpoints by selecting the closest canonical splice site to the breakpoint.
To annotate transcripts that include novel exons and/or junctions, we parsed the CIGAR string from the alignment to the metagene, to identify the combination of exon junctions supported by each read. We subsequently clustered splicing patterns to annotate a unique set of isoforms for CACNA1C and enable their expression quantification. We applied a similar approach to annotate the transcripts containing novel splice sites. We filtered exons and transcripts of low abundance (i.e. supported only by one read), and clustered transcripts together to call only their longest possible variants.
Transcript expression both on exon and splice site levels was quantified using the number of reads supporting the transcript model. Reads mapping to multiple transcripts were downweighted according to the number of transcripts they could be mapped to. Read counts were normalized across libraries using the trimmed Mean of M-values normalization method (TMM) 40 . For visualisation, all normalized counts were log 10 -transformed. Expression heatmaps and PCA plots were generated using R statistical language 41 , by heatmap3 42 and ggplot2 libraries 43 , respectively. To normalise for the difference in sequencing depth between samples, we downsampled all libraries to match that with the smallest sequencing depth and recomputed transcript expression patterns.
Quality control
A subset of novel exons and novel exon junctions found in CACNA1C by nanopore sequencing (Supplementary Table 2 ) were confirmed by PCR targeting the novel sequence followed by Sanger sequencing (See Supplementary Information for details).
RNA extracted post mortem shows variable degradation, and its quality is usually assessed using the RNA integrity number (RIN). In order to identify the minimum RIN required for reliable amplification of the full-length CDS of CACNA1C, RNA samples were artificially degraded (Supplementary Figure 1) . CACNA1C CDS amplification in these artificiallydegraded samples was assessed alongside that from striatal RNA samples of varying RINs from three adult donors (Supplementary Table 3 ).
Results
We successfully amplified and sequenced the full length ~6.5kb CACNA1C CDS (encompassing the full intron chain of CACNA1C) from all samples ( Figure 1A) . A minimum RIN of 6 is required, and a RIN of >7 is optimal, for amplification of full-length CACNA1C Tables 4 and 5 ). Most pass reads were full length, with the updated flowcell used in Run2 providing higher quality reads with a lower error rate ( Figure 1 ). All analyses were performed using the 2D pass barcoded reads, hereafter referred to simply as "reads".
Long-range amplicon sequencing reveals many novel CACNA1C exons and isoforms
We developed a bespoke alignment and mapping pipeline to maximise the transcript information obtained from nanopore sequencing reads, including the identification of novel exons, acceptor and donor splice sites, and splice junctions (Supplementary Figure 2) .
Because of CACNA1C's complexity, we used two complementary approaches to identify transcripts: exon-level and splice-site level analyses. These combined approaches identified a total of 251 unique CACNA1C transcript isoforms present in human brain, 241 of which are novel, including the use of novel exons, novel splice sites and junctions. The identity of these transcripts will be made available as a track hub that can be viewed on the UCSC Genome Browser on publication.
Exon-level analysis
We annotated a total of 39 potential novel exons within the CACNA1C locus, of which 38
were identified in at least 2 individuals or tissues and supported by at least 5 nanopore reads in each library ( Figure 2A ; Supplementary Data Table 1 ).
We validated four out of four of the novel exons (selected across the range of abundance) by PCR and Sanger sequencing by confirming the splice junctions between the novel exon and its surrounding annotated exons. We also discovered a fifth novel exon that was spliced in between the targeted novel exon and the nearest known exon. This successful validation of a selection of novel exons provides high confidence that the novel exons identified by nanopore sequencing are real and actively incorporated into CACNA1C transcripts.
Integration of these 38 novel exons and the mapping of the reads to the metagene enabled 
Splice-site level analysis
The exon-level transcript identification approach described above provides a robust and conservative means to identify novel exons and to characterise full-length transcript structure.
However, it is relatively insensitive to small-scale variation (of the order of a few amino acids). Therefore, we also implemented a splice junction-level analysis to annotate novel splice sites and junctions in the CACNA1C gene model. We used a conservative approach, which relies on the identification of junctions supported by error-free mapping at the junction, and the presence of canonical splice sites. We thereby identified 497 novel splice sites, of which 393 were supported by at least 10 reads. Compared to previously annotated splice sites, novel donor and acceptor splice sites are less used (Supplementary Figure 4) .
Including these splice sites, and after filtering for transcripts supported by at least 24 reads, we identified 195 transcripts, of which 111 are predicted to be coding (see Supplementary Data Files 6 and 7 for transcript identity and abundance, respectively). 28 of these were identical to transcripts identified by the exon-level analysis. Strikingly, most of the remainder (130) resulted from small-scale (≤15 nucleotides) differences to our high-confidence exonlevel transcripts, demonstrating the complementarity of these approaches. We validated the presence of specific small-scale deletions (3 and 4 amino acid microdeletions, described below) using Sanger sequencing.
The expression profile of CACNA1C isoforms differs between brain regions
We examined how CACNA1C isoform expression varies across brain regions and between individuals, focussing on transcripts identified using the exon-level approach (similar results were obtained using the splice-site level transcripts [Supplementary Figure 4) . We downsampled all libraries to 2,729 (the smallest sequencing depth) prior to normalization.
Differences between tissues is the main driver of the observed variation in expression between transcripts. Cerebellum and striatum were distinct from the four regions of the cortex Although we did not find any tissue-specific transcripts amongst our set of high confidence transcripts, we observed a pronounced transcript expression switch in cerebellum. Outside of the cerebellum ENST00000399641 was the dominant transcript, whilst in cerebellum, ENST00000399641 and CACNA1C n2199 were expressed at similar levels ( Figure 3C ). linker (corresponding to amino acids D306-E310 in Uniprot entry Q13936). The 4 amino acid microdeletion was previously described in heart but not brain 29 , but the 3 and 5 amino acid microdeletions are novel ( Figure 4B ). Their functional impact is unknown but the S5-S6 linker is part of the pore-forming region and these microdeletions fall within a region previously implicated in determining channel conductance 46 .
Predicted impact of novel isoforms on the
Discussion
We combined long-range RT-PCR with nanopore sequencing in order to characterize the full coding sequence from transcripts of CACNA1C. . We anticipate that long-read sequencing applications will further help decipher transcript expression and splicing, especially for genes expressed in the brain, which exhibits prominent use of alternative splicing and tissue specific exons [14] [15] [16] [17] [18] 49 .
Our study highlights the power of long read sequencing for the annotation and characterisation of alternatively spliced transcripts. We demonstrate a five-fold increase in the number of annotated transcripts for CACNA1C, identifying novel exons and deletions within the coding sequence, as well as novel combinations of previously annotated exons.
Because of the high quality of the genomic assembly at the CACNA1C locus 50 , the novel exons, and splice sites we describe are unlikely to result from mapping errors. Instead, our findings support those from transcriptome analyses that indicate that a significant proportion of gene isoforms in human brain remain unannotated 51 . Supporting their potential importance, a number of the novel transcripts are highly abundant individually, and collectively they encompass the majority of reads. Our finding that the vast majority of reads from novel transcripts maintain the CACNA1C reading frame also supports the hypothesis that these are functionally relevant and not simply products of "noisy" splicing. may be possible to selectively target disease-relevant CACNA1C isoforms and/or those that are differentially expressed in the brain vs. the periphery, to provide novel psychotropic agents that are both more potent and are freer from peripheral side effects.
Our results indicate differences in the abundance, but not the identity, of CACNA1C transcripts between brain regions. Utilising our more conservative exon-level analysis, in most regions there is a single major CACNA1C isoform, with levels of expression almost fivefold higher than the second most highly expressed transcript. However, in the cerebellum there is a switch in transcript abundance, such that the two most abundant transcripts are expressed at similar levels to one another. The consistent nature of this switch in different individuals supports the hypothesis that this is a regulated switch in expression. In contrast, our analysis demonstrated only minor differences in the transcript profile between individuals ( Figure 3B ). Given these findings, we are therefore confident that our analysis is likely to have identified most common and abundant CACNA1C transcripts present in adult human brain. However, we anticipate that the relative abundance of these transcripts will likely differ between individuals. Our splice site-level anlaysis found broadly the same results, although there was no longer a single dominant isoform in each region, largely due to variation in the IS5-6 linker. While we have validated these variations, increased certainty in their abundance and impact on overall transcript structure will likely require further improvements in exon boundary identification with nanopore sequencing. The details of the CACNA1C transcript structure revealed here will facilitate the mining of existing large-scale RNA-Seq datasets to investigate these differences between individuals (and between subgroups based on e.g. genotype or disease status).
In summary, our findings demonstrate the utility of long-range amplicon sequencing for the identification and characterisation of gene isoform profiles. More specifically, they demonstrate that the human brain CACNA1C transcriptional profile is substantially more complex than currently appreciated. Our approach focused on annotated 5' and 3' ends;
thus, there is a need for further in depth investigation, e.g. using RACE and capture sequencing. Understanding the functional consequences of this isoform diversity will advance our understanding of the role of VGCCs in the human brain and their involvement in psychiatric disorders [2] [3] [4] . Finally, some of the novel isoforms we present here may prove novel and selective therapeutic targets for these disorders 54 .
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Supplementary Information Supplementary Methods
All molecular biology protocols were conducted according to manufacturer's recommendations unless specifically noted otherwise.
RNA extraction and RT-PCR
RNA was extracted from cerebellum, striatum, dorsolateral prefrontal cortex [DLPFC], cingulate cortex, occipital cortex and parietal cortex. Tissue was disrupted with the TissueLyser LT (Qiagen, UK) using Rnase-free 5mm stainless steel beads in QIAzol Lysis Reagent (Qiagen). RNA was extracted using the Qiagen RNeasy Lipid Tissue Mini Kit (Qiagen, UK) and eluted in RNase-free water. RNA concentration and RNA integrity (RNA Integrity Number equivalent; RINe) were measured using a Tapestation 2200 (Agilent, UK). All samples had a RINe of >7.0. RNA (1µg per sample) was converted into cDNA with GoScript TM Reverse Transcriptase (Promega, UK) using oligoDT priming.
Full-length CDS amplicons of CACNA1C were obtained by PCR using primers located 5' to the translation start site in Exon 1B and 3' to the stop codon in the 3' untranslated region. Specifically, CACNA1C was amplified from cDNA equating to 125ng RNA template from the eighteen human brain samples using PrimeSTAR GXL DNA Polymerase (Takara). Tailed primers were designed to amplify the ~6.5kb CACNA1C coding sequence and included sequence to allow further amplification and barcoding. Forward and Reverse primers were tttctgttggtgctgatattgcCATTTCTTCCTCTTCGTGGCTGC and acttgcctgtcgctctatcttcCCAGGTCACGAGAACAGTGAGG, respectively (CACNA1C sequence in capital letters). Amplification was conducted for 25 cycles of 98 o C for 10 sec; 57 o C for 15 sec; 68 o C for 7 min. PCR products were separated on a 1.5% agarose gel (visualised with GelGreen, Biotium, UK). Full-length CDS (~6.5kb) products were excised and purified using the Qiagen Gel Purification Kit (Qiagen, UK). DNA was barcoded using the Oxford Nanopore Technologies (ONT) PCR Barcoding Kit (EXP-PBC001) using PrimeSTAR GXL DNA Polymerase and 12 cycles of PCR amplification, as described above. PCR products were purified with the Qiagen PCR Purification Kit (Qiagen, UK) and quantified by Qubit (ThermoFisher, UK).
Nanopore Sequencing of the full-length CACNA1C CDS
The PCR Barcoding Kit (EXP-PBC001, ONT) contains unique twelve barcodes, hence the 18 samples were split across two flowcells with 12 samples run on each. Six samples were sequenced on both flowcells to allow comparison and normalisation between sequencing runs. Samples and barcodes used in each sequencing run are described in Supplementary  Table 4. For each sequencing run, 132ng of each of the twelve samples was pooled and re-purified using 0.4x Agencourt Ampure XP beads (Beckman Coulter, UK) to concentrate the sample and remove any contaminating small DNA products. The presence of full-length DNA product in the pool was confirmed by 2200 or 4200 TapeStation (Agilent) analysis using gDNA screentape (Supplementary Figure 8) and the sample measured again by Qubit to ensure the presence of sufficient product for nanopore library preparation.
Sequencing libraries were prepared with the 2D Nanopore Sequencing Kit (SQK-LSK208, ONT) using 1µg of CACNA1C DNA. DNA end-repair and dA-tailing was performed using the NEBNext Ultra II End-Repair/dA-tailing Module (NEB, UK) in a total reaction volume of 60µl (50µl DNA, nuclease-free water (NFW) and DNA calibration strand (Run1 only), 7 μ l Ultra II End-Prep buffer and 3 μ l Ultra II End-Prep enzyme) for 5 min at 20ºC and 5 min at 65ºC. Samples were purified using 0.6x Ampure XP beads and eluted in 31µl of NFW. Sample concentrations were measured by Qubit and confirmed retention of >85% of the initial samples. The total volume of CACNA1C DNA was utilised for subsequent ligation of sequencing adaptors. Ligation reactions contained 50µl Blunt / TA Ligase Master Mix (NEB), 10 μ l Adapter Mix 2D, 2 μ l Hairpin Adaptor (HPA), 30µl of DNA and 8µl of NFW and incubations were performed at room temperature. After 10 min incubation 1 μ l Hairpin Tether (HPT) was added, the sample mixed and incubated for a further 10 minutes. Adapted DNA was purified with MyOne C1 beads (ThermoFisher). 50μl of beads were washed 2x in 100μl bead binding buffer (BBB) and resuspended in 100μl BBB before use. Beads were mixed 1:1 with adapted DNA, incubated on a rotor for 5 min at room temperature to bind DNA to the beads and collected using a magnetic stand. Bead-bound DNA was washed 2x with 150μl of BBB on the magnetic stand and left briefly to dry the beads. Beads were resuspended in 15μl of elution buffer (ELB) and incubated at 37ºC for 10 min to elute DNA from the beads. After pelleting the beads on the magnetic stand, 14μl of supernatant containing the adapted DNA library in ELB was collected. Library concentrations were measured by Qubit, recovering >25% of the original starting amount. Table 5 ) were generated by Poretools (Loman and Quinlan 2014) and PycoQC (Leger and Leonardi 2018).
Validation of novel exons and junctions
In the case of novel exons, two sets of nested PCRs were conducted: one spanning the upstream exon and the novel exon sequence ('5' confirmation' in Supplementary Table 2) , and a second spanning the novel exon sequence and the downstream exon ('3' confirmation' in Supplementary Table 2 ). Novel junctions were confirmed using a single round of PCR using one primer spanning the novel junction, with the second primer located in the neighboring exon. PCR reactions were performed using iIlustra PuReTaq Ready-To-Go PCR beads (GE Healthcare Life Sciences, UK). PCR reactions were cycled as follows: 95 o C for 5 min; 35 cycles of 95 o C for 35 sec, 30 sec at annealing temperature (see Supplementary  Table 2) ; 72 o C for 2 min, followed by a final 5 min extension at 72 o C. Primers sequences and conditions are shown in Supplementary Table 2. PCR products were separated on agarose gels. Products of the predicted size were excised, cleaned using the Qiagen Gel Extraction Kit and ligated into pGEM-T Easy vector (Promega) for Sanger sequencing. Reverse transcription used 500 ng of RNA and was performed using GoScript TM Reverse Transcriptase. CACNA1C amplification was performed as described above, using 5μl of cDNA and 30 cycles of amplification. Forward and Reverse primers were: CATTTCTTCCTCTTCGTGGCTGC and CCAGGTCACGAGAACAGTGAGG, respectively, i.e. identical to those used in the main experiment, but lacking the barcoding tails. Successful amplification of PCR product was confirmed and visualised using both agarose gel electrophoresis and 4200 Tapestation analysis using equal proportions of each PCR. Samples from three additional adult donors were utilised specifically for this experiment to provide the required range of high quality and partially degraded samples. 
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